Ramy A. Ibrahim
67 works · 8,435 citations · h-index 28
Top works
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- Improved Endpoints for Cancer Immunotherapy Trials
- An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy
- Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
- Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)
- Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment
- Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy
- Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
- Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.
- Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.
- Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.
- Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials
- A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.
- Future cancer research priorities in the USA: a Lancet Oncology Commission
- Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity
- PD-L1 Blockade for Cancer Treatment: MEDI4736
- Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients.
- Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels